表紙
市場調查報告書

脊索瘤治療藥市場:各藥物類別、治療類型、終端用戶、地區 - 市場規模,佔有率,預測,及機會分析

Chordoma Disease Therapeutics Market, by Drug Class, by Treatment Type, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 948417
出版日期 內容資訊 英文 201 Pages
商品交期: 2-3個工作天內
價格
脊索瘤治療藥市場:各藥物類別、治療類型、終端用戶、地區 - 市場規模,佔有率,預測,及機會分析 Chordoma Disease Therapeutics Market, by Drug Class, by Treatment Type, by End User, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2020年07月08日內容資訊: 英文 201 Pages
簡介

脊索瘤,是有許多治療上限制的稀少種類的癌症。全球脊索瘤治療藥市場,由於為了開發先進治療方法的主要市場參與企業的研究開發活動的增加,在預測期間內預期成長。

本報告提供全球脊索瘤治療藥市場的相關調查,市場機會和趨勢,成長及阻礙因素,各藥物類型、治療類型、終端用戶、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 調查目的、前提條件

第2章 市場展望

  • 報告的說明
    • 市場定義和範圍
  • 摘要整理
    • 市場明細 :各類藥物
    • 市場明細 :各治療類型
    • 市場明細 :終端用戶
    • 市場明細 :各地區
  • Coherent Opportunity Map (COM)

第3章 市場動態,法規,趨勢分析

  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 主要的發展
  • PEST分析

第4章 COVID-19大流行的影響

  • 衝擊調查
  • COVID-19大流行以前的市場方案
  • COVID-19大流行後的市場方案
  • 政府對COVID-19的措施

第1章 市場分析:各類藥物

  • 簡介
  • 代謝拮抗劑
  • 蒽環
  • VEGFR抑制劑
  • EGFR抑制劑
  • 其他

第2章 市場分析:各治療類型

  • 簡介
  • 化療
  • 標靶治療
  • 放射治療
  • 其他

第3章 市場分析:各終端用戶

  • 簡介
  • 醫院
  • 醫院
  • 腫瘤中心
  • 其他

第4章 市場分析:各地區

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第5章 競爭情形

  • 熱圖分析
  • 市場佔有率分析
    • GlaxoSmithKline Plc
    • Bavarian Nordic
    • Boehringer Ingelheim International GmbH
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • Sanofi SA
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • Amgen, Inc.
    • Bristol-Myers Squibb and Company
    • Novartis International AG
    • Bayer AG
    • Dr. Reddy's Laboratories Ltd.
    • Mylan N.V.
  • 分析師的見解

第6章 Section

目錄

Title:
Chordoma Disease Therapeutics Market, by Drug Class (Antimetabolites, Anthracycline, VEGFR Inhibitors, EGFR Inhibitor, and Others), by Treatment Type (Chemotherapy, Targeted Therapy, Radiation Therapy, and Others), by End User (Hospitals, Clinics, Oncology Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Chordoma is a rare cancer along with many treatment limitations. The tumor grows slowly in the bones of skull and spine when an individual is suffering from chordoma. Around half of all chordomas occur at the sacrum (base of the spine), approximately one third occur in the occiput (base of the skull), while rest of the chordomas occur in the cervical (neck), thoracic (upper back) or lumbar (lower back) vertebrae of the spine. A chordoma growth in the spine region may cause weakness, pain or numbness in the back, legs or arms. An occipital chordoma (chordoma at the base of skull) may lead to diplopia (double vision) and headaches while coccygeal chordoma (chordoma occurring in the tailbone) may result in a large lump, which may cause problems with bladder or bowel function.

Although chordoma is a rare type of cancer, increasing research and development activities for its treatment is likely to drive growth of the chordoma disease therapeutics market over the forecast period.

Market Dynamics

The increasing number of research and development activities by key players operating in the market, in order to develop advanced treatment for chordoma, is expected to propel the market growth over the forecast period. For instance, in June 2018, Boehringer Ingelheim, a pharmaceutical company, initiated phase 2 clinical trial in collaboration with the Chordoma Foundation, a non-profit organization. The purpose of the trial was to evaluate the safety and efficacy of Afatinib, a tyrosine kinase inhibitor, as first line or later line treatment in advanced chordoma.

Key features of the study:

  • This report provides in-depth analysis of the global chordoma disease therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global chordoma disease therapeutics market based on the following parameters - company overview, financial performance, Drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include GlaxoSmithKline Plc, Bavarian Nordic A/S, Boehringer Ingelheim International GmbH, Pfizer, Inc., Merck & Co., Inc., Sanofi SA, Astellas Pharma Inc., AstraZeneca plc, Amgen, Inc., Bristol-Myers Squibb and Company, Novartis International AG, Bayer AG, Dr. Reddy's Laboratories Ltd., and Mylan N.V.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future drug launches, drug class up-gradation, market expansion, and marketing tactics
  • The global chordoma disease therapeutics market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chordoma disease therapeutics market

Detailed Segmentation:

  • Global Chordoma Disease Therapeutics Market, By Drug Class:
    • Antimetabolites
    • Anthracycline
    • VEGFR Inhibitors
    • EGFR Inhibitor
    • Others
  • Global Chordoma Disease Therapeutics Market, By Treatment Type:
    • Chemotherapy
    • Targeted Therapy
    • Radiation Therapy
    • Others
  • Global Chordoma Disease Therapeutics Market, By End User:
    • Hospitals
    • Clinics
    • Oncology Centers
    • Others
  • Global Chordoma Disease Therapeutics Market, By Region:
    • North America
      • By Drug Class:
      • Antimetabolites
      • Anthracycline
      • VEGFR Inhibitors
      • EGFR Inhibitor
      • Others
      • By Treatment Type
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Others
      • By End User:
      • Hospitals
      • Clinics
      • Oncology Centers
      • Others
      • By Country:
      • U.S.
      • Canada
    • Latin America
      • By Drug Class:
      • Antimetabolites
      • Anthracycline
      • VEGFR Inhibitors
      • EGFR Inhibitor
      • Others
      • By Treatment Type
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Others
      • By End User:
      • Hospitals
      • Clinics
      • Oncology Centers
      • Others
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Drug Class:
      • Antimetabolites
      • Anthracycline
      • VEGFR Inhibitors
      • EGFR Inhibitor
      • Others
      • By Treatment Type
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Others
      • By End User:
      • Hospitals
      • Clinics
      • Oncology Centers
      • Others
      • By Country:
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug Class:
      • Antimetabolites
      • Anthracycline
      • VEGFR Inhibitors
      • EGFR Inhibitor
      • Others
      • By Treatment Type
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Others
      • By End User:
      • Hospitals
      • Clinics
      • Oncology Centers
      • Others
      • By Country:
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Drug Class:
      • Antimetabolites
      • Anthracycline
      • VEGFR Inhibitors
      • EGFR Inhibitor
      • Others
      • By Treatment Type
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Others
      • By End User:
      • Hospitals
      • Clinics
      • Oncology Centers
      • Others
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Class:
      • Antimetabolites
      • Anthracycline
      • VEGFR Inhibitors
      • EGFR Inhibitor
      • Others
      • By Treatment Type
      • Chemotherapy
      • Targeted Therapy
      • Radiation Therapy
      • Others
      • By End User:
      • Hospitals
      • Clinics
      • Oncology Centers
      • Others
      • By Country/Region:
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • GlaxoSmithKline Plc *
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Bavarian Nordic A/S
    • Boehringer Ingelheim International GmbH
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • Sanofi SA
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • Amgen, Inc.
    • Bristol-Myers Squibb and Company
    • Novartis International AG
    • Bayer AG
    • Dr. Reddy's Laboratories Ltd.
    • Mylan N.V.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Treatment Type
    • Market Snippet, By End User
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Key Developments
  • PEST Analysis

4. Global Chordoma Disease Therapeutics Market - Impact of Coronavirus (Covid-19) Pandemic

  • Impact assessment
  • Pre COVID-19 Market Scenario
  • Post COVID-19 Market Scenario
  • Government measures to combat COVID-19

1. Global Chordoma Disease Therapeutics Market, By Drug Class, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Antimetabolites
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Anthracycline
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • VEGFR Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • EGFR Inhibitor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

2. Global Chordoma Disease Therapeutics Market, By Treatment Type, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Chemotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Targeted Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Radiation Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

3. Global Chordoma Disease Therapeutics Market, By End User, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Oncology Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Mn)

4. Global Chordoma Disease Therapeutics Market, By Region, 2016 - 2027, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2027
  • North America
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Class, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Treatment Type, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By End User, 2016 - 2027, (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

5. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • GlaxoSmithKline Plc
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Bavarian Nordic
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Boehringer Ingelheim International GmbH
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Pfizer, Inc.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Merck & Co., Inc.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Sanofi SA
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Astellas Pharma Inc.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • AstraZeneca plc
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Amgen, Inc.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Bristol-Myers Squibb and Company
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Novartis International AG
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Bayer AG
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Dr. Reddy's Laboratories Ltd.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Mylan N.V.
    • Company Overview
    • Device Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Analyst Views

6. Section

  • References
  • Research Methodology
  • About us and Sales Contact